

因 COVID-19 大流行和其他情况而修改的试验方案和已完成试验的报告指南

Guidelines for Reporting Trial Protocols and Completed Trials Modified Due to the COVID-19 Pandemic and Other Extenuating Circumstances

The CONSERVE 2021 Statement

Aaron M. Orkin, MD, MSc, MPH^{1,2}; Peter J. Gill, MD, DPhil³; Davina Gherzi, MD, PhD⁴; Lisa Campbell, MD, MBBCh, BSc⁵; Jeremy Sugarman, MD, MPH, MA⁶; Richard Emsley, PhD⁷; Philippe Gabriel Steg, MD⁸; Charles Weijer, MD, PhD⁹; John Simes, MBBS, MD¹⁰; Tanja Rombey, MPH¹¹; Hywel C. Williams, DSc^{12,13}; Janet Wittes, PhD¹⁴; David Moher, PhD¹⁵; Dawn P. Richards, PhD¹⁶; Yvette Kasamon, MD¹⁷; Kenneth Getz, MBA¹⁸; Sally Hopewell, MSc, DPhil¹⁹; Kay Dickersin, MA, PhD²⁰; Taixiang Wu, MPH²¹; Ana Patricia Ayala, MSt²²; Kenneth F. Schulz, PhD^{23,24}; Sabine Calleja, M²⁵; Isabelle Boutron, MD, PhD²⁶; Joseph S. Ross, MD, MHS^{27,28}; Robert M. Golub, MD^{29,30}; Karim M. Khan, MD, PhD³¹; Cindy Mulrow, MD, MSc³²; Nandi Siegfried, PhD, MPH³³; Joerg Heber, PhD³⁴; Naomi Lee, MD³⁵; Pamela Reed Kearney, MD³⁶; Rhoda K. Wanyenze, MBChB, MPH, PhD³⁷; Asbjørn Hróbjartsson, MD, PhD, MPhil³⁸; Rebecca Williams, PharmD, MPH³⁹; Nita Bhandari, PhD⁴⁰; Peter Jüni, MD⁴¹; An-Wen Chan, MD, DPhil⁴²; for the CONSERVE Group

JAMA. Published online June 21, 2021. doi:10.1001/jama.2021.9941

原文链接:

<https://jamanetwork.com/journals/jama/fullarticle/2781397>